Insiders Trades
No insider purchase over the last 90 days. The latest was filed 06 May 2026.
Novonesis (Novozymes A/S): what insiders have been doing
Novonesis (Novozymes A/S), classified in the Chemicals sector, is a listed company. Its insiders report their share dealings to Finanstilsynet DK. 11 insiders have disclosed 11 filings since 18 October 2025.
Both sides are active: 4 purchases worth €286k and 1 sale worth €20k, from 4 insiders and 1 insider respectively. Netting one side against the other leaves €266k of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a purchase of €133k, disclosed on 21 November 2025.
The last purchase on record was published on 6 May 2026, which is 164 days ago. Half of the filings or more reach the Finanstilsynet DK feed on the day of the trade. The legal deadline for notifying a trade is three business days (MAR article 19).
For context, the typical company on the same exchange (median of 74 companies) published 4 filings over the same period, against 11 filings here. Since 2005, the database holds 95 purchases and 35 sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Culp Inc and Gold.com, Inc. Every figure here comes from the filings published by Finanstilsynet DK and describes the past, not future prices; it is not investment advice.
Insider Decl.
292
Thresholds
n/a
Buy Volume
€1B
95 ops. · all time
Sell Volume
€231M
35 ops. · all time
Who traded when
BuySaleUnknown15 buys2 sales
Analyst consensus: bullish or bearish?
Analysts rate Novonesis (Novozymes A/S) Buy (bullish), based on 15 analysts. Average price target: DKK 499.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 12,369 of 24,148 companies
50.9
score / 100
Value37
Quality65
FCF yld0.4%
Earn yld0.3%
EV/EBITDA·
ROE5.8%
Gross mgn54%
Net mgn14%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2024FY ended December 2024 · cache
DKK 454.80
Analyst consensus
15 analystsBuy
DKK 420.00Target DKK 499.33(+10%)DKK 540.00
Income statement
RevenueDKK 4.2B
Gross profitDKK 2.2B54% margin
EBITDADKK 1.4B33% margin
Net incomeDKK 583.6M14.7% margin
Valuation
PER (trailing)44.8x
PER (forward)25.3x
P/Book2.5x
Beta0.62
Balance sheet & cash
Market capDKK 212.1B
Total debtDKK 1.8B
Free Cash FlowDKK 750.7M
Debt / Equity28%
Profitability & ownership
ROE5.8%
ROA3.8%
% insiders15.8%
% institutions37.5%
Last declaration on 25 August 2026
Declarations292 total
12,500 shares@ DKK 446.12310.0028% mcap100.0% of flowShareXCSEISIN DK0060336014DK:1460010
2,500 shares@ DKK 393.69160.0% of flowShareOMX CopenhagenISIN DK0060336014DK:1440144
Canonical exit: 4 Aug 2026 (T+90)
400 shares@ DKK 371.800.0% of flowShareNasdaq CopenhagenISIN DK0060336014DK:1429237
4 shares@ DKK 3.000.0% of flowShareXCSEISIN DK0060336014DK:1428126
Canonical exit: 21 Jun 2026 (T+90)
725 shares@ DKK 347.400.0% of flowShareNasdaqISIN DK0060336014DK:1425698
1,500 shares@ DKK 368.100.0% of flowShareUBS SIISIN DK0060336014DK:1423171
2,700 shares@ DKK 371.98020.0% of flowShareOMX CopenhagenISIN DK0060336014DK:1422930
18,337 shares@ DKK 368.500.1% of flowShareOutside a trading venueISIN DK0060336014DK:1422788
2,500 shares@ DKK 397.07160.0% of flowShareNasdaqISIN DK0060336014DK:1402016
Canonical exit: 19 Feb 2026 (T+90)
380 shares@ DKK 418.100.0% of flowShareNasdaq XCSEISIN DK0060336014DK:1399510
Canonical exit: 5 Feb 2026 (T+90)
ShareOutside a trading venueISIN DK0060336014DK:1398579
48,610 shares@ DKK 286.09060.1% of flowShareOutside a trading venueISIN DK0060336014DK:1386700
Canonical exit: 1 Dec 2025 (T+90)
2,000 shares@ DKK 396.22920.0% of flowShare- Turquoise EuropeISIN DK0060336014DK:1385800
Canonical exit: 26 Nov 2025 (T+90)
2,000 shares@ DKK 396.22920.0% of flowShare- Turquoise EuropeISIN DK0060336014DK:1385794
Canonical exit: 26 Nov 2025 (T+90)
716 shares@ DKK 390.000.0% of flowShareNasdaq CopenhagenISIN DK0060336014DK:1384879
Canonical exit: 20 Nov 2025 (T+90)
3,000 shares@ DKK 398.490.0% of flowShareOMX CopenhagenISIN DK0060336014DK:1384811
Canonical exit: 20 Nov 2025 (T+90)
34,407 shares@ DKK 350.800.1% of flowShareOutside a trading venueISIN DK0060336014DK:1368228
Canonical exit: 8 Sept 2025 (T+90)
19,934 shares@ DKK 249.400.0% of flowShareOutside a trading venueISIN DK0060336014DK:1362576
Canonical exit: 10 Aug 2025 (T+90)
1,000 shares@ DKK 402.41460.0% of flowShareXCSEISIN DK0060336014DK:1351471
Canonical exit: 24 Jun 2025 (T+90)
26,550 shares@ DKK 249.400.1% of flowShareOutside a trading venueISIN DK0060336014DK:1347415
Canonical exit: 4 Jun 2025 (T+90)
1,000 shares@ DKK 439.500.0% of flowShareXCSEISIN DK0060336014DK:1347062
Canonical exit: 3 Jun 2025 (T+90)
1,620 shares@ DKK 425.300.0% of flowShareXCSEISIN DK0060336014DK:1346494
12,120 shares@ DKK 428.100.0% of flowShareOutside a trading venueISIN DK0060336014DK:1345683
ShareOutside a trading venueISIN DK0060336014DK:1335997
Share- Cboe Europe Equities - European Equities (Nl)ISIN DK0060336014DK:1328947
Canonical exit: 18 Feb 2025 (T+90)
25 of 292 declarations
About Novonesis (Novozymes A/S)
Novonesis is a subsidiary of Novozymes A/S, focused on developing enzymatic and biological solutions. The company emphasizes sustainable innovation for various sectors, including agriculture and food.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
